Ariel3: phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC).
Authors
Ledermann, JOza, A
Lorusso, D
Aghajanian, C
Oaknin, A
Dean, A
Colombo, N
Weberpals, J
Clamp, Andrew R
Scambia, G
Leary, A
Holloway, R
O'Malley, D
Cameron, T
Maloney, L
Goble, S
Lin, K
Sun, J
Giordano, H
Coleman, R
Affiliation
UCL Cancer Institute and UCL Hospitals, Gynecological Oncology, LondonIssue Date
2017